

PRODUCT INFORMATION

Common Name	PDL1V,PF-08046054,SGN PDL1V,SGN-PDLV,SGNPDL1V
Conjugate	Unconjugated
Synonyms	Programmed cell death 1 ligand 1, B7H1, B7-H1, PDL1, PDCD1L1, B7 homolog 1, B7 homologue 1, CD274
Applications	ELISA, Flow Cyt
Endotoxin	Less than 1.0 EU/µg by the LAL method. For <1 EU/mg requirements, please contact us for customization.
Recommended Dilutions	ELISA 1:5000-10000, Flow Cyt 1:100
Formulation & Reconstitution	Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis for specific instructions of reconstitution.
Host Species	Homo sapiens
IgG type	Human IgG1(L234A,L235A,E356D,M358L) - kappa
Reactivity	Human
Target	PD-L1
Uniprot ID	Q9NZQ7
Description	Anti-PD-L1(SGNPDL 1V biosimilar) mAb
Delivery	In Stock
Storage&Shipping	Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized antibodies are shipped at ambient temperature.
Sterility	Products are supplied non-sterile. For cell culture applications, dilute in appropriate medium and sterile-filter (0.22 µm) prior to use.
Background	Research grade biosimilar. Not for use in therapeutic or diagnostic procedures for humans or animals.
Usage	Research use only



Anti-PD-L1(SGNPDL 1V biosimilar) mAb ELISA

0.2 µg of Human PD-L1, mFc-His tagged protein per well




Figure 1. ELISA plate pre-coated by 2 µg/mL (100 µL/well) Human PD-L1 Protein, mFc-His tag(PME100023) can bind Anti-PD-L1 (SGNPDL 1V biosimilar) mAb (BME100287) in a linear range of 1.6-8.0ng/mL.




Figure 2. Flow cytometry analysis with 0.5µg/ml Anti-PD-L1(SGNPDL 1V biosimilar) mAb (BME100287) on HEK293 cells transfected with human PD-L1 (Blue histogram) or HEK293 transfected with irrelevant protein (Red histogram).



PD-1 Competitive experiment of neutralizing anti-PD-L1 antibody




Figure 3. FACS analysis showed that the binding of Biotin-PD-1 to K562 cells overexpressing PD-L1 was inhibited by increasing concentrations of neutralizing anti-PD-L1 antibodies. The concentration of Biotin-PD-1 used was 1.5 μ g/mL. BME100288 and BME100287 exhibited dose-dependent blocking activity, while the irrelevant control antibody showed no inhibition.

